Public Employees Retirement System of Ohio cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 170,169 shares of the pharmaceutical company’s stock after selling 17,152 shares during the quarter. Public Employees Retirement System of Ohio owned 0.07% of Vertex Pharmaceuticals worth $28,922,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the stock. Kaizen Advisory LLC lifted its position in shares of Vertex Pharmaceuticals by 147.3% in the second quarter. Kaizen Advisory LLC now owns 601 shares of the pharmaceutical company’s stock valued at $102,000 after acquiring an additional 358 shares in the last quarter. Mount Yale Investment Advisors LLC acquired a new position in Vertex Pharmaceuticals in the first quarter valued at $101,000. Sun Life Financial INC increased its stake in Vertex Pharmaceuticals by 266.1% in the second quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock valued at $118,000 after purchasing an additional 503 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in Vertex Pharmaceuticals in the second quarter valued at $125,000. Finally, Migdal Insurance & Financial Holdings Ltd. increased its stake in Vertex Pharmaceuticals by 3,126.1% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 742 shares of the pharmaceutical company’s stock valued at $126,000 after purchasing an additional 719 shares during the last quarter. Hedge funds and other institutional investors own 93.47% of the company’s stock.

VRTX traded up $5.66 on Friday, reaching $181.32. The company’s stock had a trading volume of 1,198,957 shares, compared to its average volume of 1,528,475. The company has a market capitalization of $49.26 billion, a P/E ratio of 226.65, a P/E/G ratio of 1.96 and a beta of 1.48. Vertex Pharmaceuticals Incorporated has a 1 year low of $136.50 and a 1 year high of $194.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.55 and a current ratio of 3.67.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 25th. The pharmaceutical company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.40 by $0.54. The firm had revenue of $752.20 million during the quarter, compared to the consensus estimate of $680.86 million. Vertex Pharmaceuticals had a return on equity of 19.86% and a net margin of 15.84%. Vertex Pharmaceuticals’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.39 earnings per share. As a group, equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 2.48 earnings per share for the current fiscal year.

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 2,445 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $194.62, for a total transaction of $475,845.90. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Paul M. Silva sold 860 shares of the stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $179.85, for a total value of $154,671.00. Following the transaction, the senior vice president now directly owns 16,947 shares in the company, valued at approximately $3,047,917.95. The disclosure for this sale can be found here. Insiders sold 40,560 shares of company stock valued at $7,436,746 in the last three months. 0.75% of the stock is currently owned by company insiders.

Several equities analysts recently commented on VRTX shares. Argus upped their target price on Vertex Pharmaceuticals to $200.00 and gave the company an “average” rating in a research note on Tuesday, August 28th. They noted that the move was a valuation call. Stifel Nicolaus upped their target price on Vertex Pharmaceuticals from $182.00 to $200.00 and gave the company a “buy” rating in a research note on Tuesday, August 7th. Citigroup upped their target price on Vertex Pharmaceuticals from $203.00 to $206.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Royal Bank of Canada reiterated a “buy” rating and issued a $203.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, July 26th. Finally, Jefferies Financial Group upped their price target on Vertex Pharmaceuticals to $210.00 and gave the stock a “buy” rating in a research note on Monday, July 16th. Four research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $197.68.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

See Also: Do stock splits help investors?

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.